Introduction: Adjustable intragastric balloon (aIGB), as known as a novel minimally invasive therapy for obesity, provide a sustained alternative for weight loss. Weight loss is achieved by implanting
Original raw data extracted from MAUDE using product code KZH for period of January 1, 2008, to September 30, 2023. The last update from the FDA as of September 30, 2023.
